BACKGROUND: Inhibition of early platelet adhesion by blockade of glycoprotein-IB (GPIb) protects mice from ischemic stroke. To elucidate underlying mechanisms in-vivo, infarct development was followed by ultra-high field MRI at 17.6 Tesla. METHODS: Cerebral infarction was induced by transient-middle-cerebral-artery-occlusion (tMCAO) for 1 hour in C57/BL6 control mice (N = 10) and mice treated with 100 µg Fab-fragments of the GPIb blocking antibody p0p/B 1 h after tMCAO (N = 10). To control for the effect of reperfusion, additional mice underwent permanent occlusion and received anti-GPIb treatment (N = 6; pMCAO) or remained without treatment (N = 3; pMCAO). MRI 2 h and 24 h after MCAO measured cerebral-blood-flow (CBF) by continuous arterial-spin labelling, the apparent-diffusion-coefficient (ADC), quantitative-T2 and T2-weighted imaging. All images were registered to a standard mouse brain MRI atlas and statistically analysed voxel-wise, and by cortico-subcortical ROI analysis. RESULTS: Anti-GPIb treatment led to a relative increase of postischemic CBF vs. controls in the cortical territory of the MCA (2 h: 44.2±6.9 ml/100 g/min versus 24 h: 60.5±8.4; p = 0.0012, F((1,18)) = 14.63) after tMCAO. Subcortical CBF 2 h after tMCAO was higher in anti-GPIb treated animals (45.3±5.9 vs. controls: 33.6±4.3; p = 0.04). In both regions, CBF findings were clearly related to a lower probability of infarction (Cortex/Subcortex of treated group: 35%/65% vs. controls: 95%/100%) and improved quantitative-T2 and ADC. After pMCAO, anti-GPIb treated mice developed similar infarcts preceded by severe irreversible hypoperfusion as controls after tMCAO indicating dependency of stroke protection on reperfusion. CONCLUSION: Blockade of platelet adhesion by anti-GPIb-Fab-fragments results in substantially improved CBF early during reperfusion. This finding was in exact spatial correspondence with the prevention of cerebral infarction and indicates in-vivo an increased patency of the microcirculation. Thus, progression of infarction during early ischemia and reperfusion can be mitigated by anti-platelet treatment.
BACKGROUND: Inhibition of early platelet adhesion by blockade of glycoprotein-IB (GPIb) protects mice from ischemic stroke. To elucidate underlying mechanisms in-vivo, infarct development was followed by ultra-high field MRI at 17.6 Tesla. METHODS:Cerebral infarction was induced by transient-middle-cerebral-artery-occlusion (tMCAO) for 1 hour in C57/BL6 control mice (N = 10) and mice treated with 100 µg Fab-fragments of the GPIb blocking antibody p0p/B 1 h after tMCAO (N = 10). To control for the effect of reperfusion, additional mice underwent permanent occlusion and received anti-GPIb treatment (N = 6; pMCAO) or remained without treatment (N = 3; pMCAO). MRI 2 h and 24 h after MCAO measured cerebral-blood-flow (CBF) by continuous arterial-spin labelling, the apparent-diffusion-coefficient (ADC), quantitative-T2 and T2-weighted imaging. All images were registered to a standard mouse brain MRI atlas and statistically analysed voxel-wise, and by cortico-subcortical ROI analysis. RESULTS: Anti-GPIb treatment led to a relative increase of postischemic CBF vs. controls in the cortical territory of the MCA (2 h: 44.2±6.9 ml/100 g/min versus 24 h: 60.5±8.4; p = 0.0012, F((1,18)) = 14.63) after tMCAO. Subcortical CBF 2 h after tMCAO was higher in anti-GPIb treated animals (45.3±5.9 vs. controls: 33.6±4.3; p = 0.04). In both regions, CBF findings were clearly related to a lower probability of infarction (Cortex/Subcortex of treated group: 35%/65% vs. controls: 95%/100%) and improved quantitative-T2 and ADC. After pMCAO, anti-GPIb treated mice developed similar infarcts preceded by severe irreversible hypoperfusion as controls after tMCAO indicating dependency of stroke protection on reperfusion. CONCLUSION: Blockade of platelet adhesion by anti-GPIb-Fab-fragments results in substantially improved CBF early during reperfusion. This finding was in exact spatial correspondence with the prevention of cerebral infarction and indicates in-vivo an increased patency of the microcirculation. Thus, progression of infarction during early ischemia and reperfusion can be mitigated by anti-platelet treatment.
Ischemic stroke is a major cause of death and disability [1]. A significant proportion of
strokes are caused by thromboembolic occlusion of major intracerebral vessels such
as the middle cerebral artery (MCA). The complex cellular and molecular processes
underlying the development of ischemic brain lesions are incompletely understood
[2], [3]. This also
applies to the situations in which extended and clinically severe strokes evolve
despite “favorable” removal of the vessel occluding clot either
spontaneously or by thrombolysis giving rise to reperfusion [4], [5]. Reperfusion is a prerequisite
for replenishing brain areas at risk for infarction with oxygen and nutritional
factors, but, on the other hand, elicits detrimental processes referred to as
reperfusion injury. We could recently show that interference
with critical steps of platelet tethering to the vessel wall can prevent ischemic
stroke in the mouse model of transient MCA occlusion
(MCAO) [6], [7].The initial tethering of
platelets at sites of vascular injury is mediated by GPIb-V-IX, a structurally
unique receptor complex exclusively expressed in platelets and megakaryocytes [8]. GPIbα
is indispensable for platelet adhesion under conditions of high shear such as in the
arterial cerebrovascular system. Inhibition of the von Willebrand factor
(vWF)-binding site of GPIbα with Fab fragments of the antibody p0p/B in
wild-type mice abrogated platelet tethering and adhesion in a model of mechanically
induced arterial thrombosis as well as in ischemic stroke, while unspecific Fab
fragments had no effect [7]. Cerebral infarcts were significantly smaller when
assessed histologically or by 1.5T MRI. These findings make GPIb an attractive
target for clinical development of an antithrombotic drug in acute stroke.There is recent evidence that GPIb, so far mainly regarded as instrumental in
haemostasis and thrombus formation, can profoundly guide inflammation [9]. Thus, the effect
of GPIb blockade in cerebral ischemia could be due to sustained patency of blood
vessels during reperfusion or, alternatively, due to a primary anti-inflammatory
effect [10]. To
address this important issue, we employed multimodal MRI at ultra-high-field
strength (UHF-MRI) to monitor lesion development in relation to cerebral blood flow
in GPIb-Fab-treated mice and naive controls after
MCAO. As principal finding, we show that
cerebral perfusion after MCAO is sustained in
GPIb-treated mice after removal of the vessel occluding thread while in normal mice
perfusion further decreases leading to progressive stroke. Thus,
anti-GPIb treatment substantially ameliorates infarct
progression during early ischemia and reperfusion.
Materials and Methods
Experimental design and animal stroke model
All procedures and animal studies were approved by the Regierung von Unterfranken
(Wuerzburg, Germany, approval number: 55.2-2531.01-23/04 and -55/09) and
conducted in accordance with the recommendations for the performance of basic
experimental stroke studies as previously published [11].The main experimental group in this study were anti-GP1b treated mice (adult male
C57/BL6 mice weighing 20–25 g (Charles River, Sulzfeld, Germany)
undergoing one hour of MCAO
(N = 10). These mice received 100 µg p0p/B Fab
fragments [12] intravenously 1 hour after
MCAO, that is, after 1 hour of
occlusion at the time point at which the thread was removed. This regimen led to
significantly smaller infarcts compared to control-treated animals in our
previous study [7]. In the present study we used naive mice (adult male
C57/BL6 mice weighing 20–25 g (Charles River, Sulzfeld, Germany) as
controls for the efficacy to induce full-blown MCA infarcts by 1 hour of
MCAO(N = 10)
because in our previous study there was no difference between naive mice and
mice treated with an unspecific Fab fragment [7]. To investigate
whether reperfusion is required for the therapeutic effect of GPIb blockade,
additional anti-GPIb treated mice (N = 6) and control mice
(N = 3) underwent permanent MCAO
(MCAO). Furthermore, another group
of control mice underwent sham operation (N = 3).The experimental procedures were performed as described in detail previously
[7],
[13], [14]. Briefly, a standardized suture coated with silicon
rubber (6021PK10; Doccol Company, Redlands, CA, USA) was introduced into the
right common carotid artery and advanced over the internal carotid artery to the
origin of the MCA. The suture was fixed and left in situ and animals were
allowed to recover. Operation time per animal did not exceed 15 minutes. After
60 min. animals were re-anesthetized and the suture was withdrawn to allow
tissue reperfusion (MCAO). For
MCAO, the thread was left within
the vessel until the end of the experiments at day 1. Sham operation included
preparation of the common carotid artery and ligation of its branches without
thread insertion. The operations were performed under inhalation anesthesia
(2.0% isoflurane in a 70%/30% N2O/O2
mixture) and the body temperature was maintained at 37°C using a
servo-controlled heating pad. All subjects were subsequently followed in-vivo by
serial multimodal UHF-MRI at 2 h and 24 h.An additional group of anti-GP1b treated mice was investigated
at an even earlier time point after tMCAO, i.e. 1 h after thread removal, to
address the question whether the observed hypoperfusion at 2 h is preceded by
hyperperfusion. In this scenario, a deleterious effect of reperfusion on tissue
fate (reperfusion injury) might be functional rather than a beneficial effect of
sustained reperfusion for the prevention of infarct progression under
anti-GP1b treatment. In our local experimental setting of
multimodal UHF-MRI, logistic circumstances restrict the earliest time point
applicable for data acquisition to around 1 h after removal of the thread.
Multimodal UHF-MRI of experimental cerebral ischemia in-vivo
A detailed description of the imaging protocol is given in previous work [15]. Cerebral
perfusion was measured using a modified arterial spin labeling (CASL) method
[16],
[17], [18]. To benefit
especially from increased longitudinal magnetization and the elevation of the T1
relaxation time for detailed anatomical mapping of CBF and group analysis, all
measurements were performed at ultra-high magnetic field strength (Avance 17.6T,
750 MHz, Bruker BioSpin GmbH, Ettlingen, Germany). Image maps of cerebral
perfusion were calculated on a pixel-by-pixel basis according to Detre et al.
[18]. The
degree of the inversion efficiency was assumed to be
alpha = 0.7 [19], [20]. In close approximation to
the value recently reported by Leithner et al. for the mouse brain [21] the
brain-blood partition coefficient value for water was assumed to be
lambda = 0.90 mL/g. Slice selective T1 mapping was measured
with a single slice partial saturation inversion recovery RARE sequence (TI of
0.02 s, 0.5 s, 1.0 s, 1.5 s, 2.0 s, 3.0 s, 5.0 s, 10.0 s). The recovery time
after acquisition of each image was 10 s
(echo-train-length = 16,
TEeff = 30 ms). Inversion of magnetization was
performed by a 6 mm slice selective adiabatic hypersecant pulse. T1 relaxation
time constants were calculated voxel-wise applying first, a 3 parameter fit to
estimate the efficiency of the inversion pulse and then, a 2 parameter fit with
a fixed averaged value for the inversion pulse efficiency typically between
95% and 97%.Diffusion weighted imaging (DWI) was performed with a pulsed-field gradient
Setjskal-Tanner-like multislice spin echo sequence because echo-planar-imaging
suffers from extreme susceptibility artifacts at ultra-high magnetic field
strength. Diffusion sensitization was only performed along the slice direction
to keep the overall acquisition time low [22]. Images with different
b-values, 0 and 800 s/mm2, were acquired to allow for the calculation
of apparent diffusion coefficient (ADC) maps of brain water. Whole brain
coverage was achieved by thirteen coronal slices acquired with a matrix size of
64×64, FOV 1.8×1.8 cm, in plane resolution 281×281 µm,
slice thickness = 0.5 mm, interslice
distance = 1 mm, TE/TR = 22.3/2000 ms.
Repeated measurement of the b = 800 s/mm2 DWI
experiments (number of repetition NR = 3) led to an overall
acquisition time for diffusion weighted experiments of 8 min. ADC maps were
calculated by applying the common equation
ADC = −0.00125×ln
(SIB800/SIB0). The b value of 800 s/mm2 was
chosen to maintain a high signal-to-noise ratio for each acquisition, in case
motion artifacts of the spin echo DWI sequence would degrade other
acquisitions.T2 relaxometric mapping was performed for the in-vivo delineation of infarcted
brain tissue at 24 h. Single slice T2-weighted (T2-w) imaging was performed
using a Carr-Purcell-Meiboom-Gill (CPMG) multi-spin echo sequence collecting
thirty two echoes at TR/TE = 4.2/2000 ms. T2 relaxation
times constants were calculated voxel-wise by fitting the intensities of the 20
first echoes to a monoexponential model. CBF, T1 and T2 relaxometric maps were
measured each with the exact same geometry for a 1.5 mm thick slab centered at
the bregma as the operational definition of the central MCA territory.For high-resolution structural imaging with whole-brain coverage, an additional
strongly T2 weighted 2D turbo spin-echo sequence was acquired (RARE factor 16,
TR = 8 s, effective TE = 56.44 ms, 2
averages, 13 coronal slices with an image matrix of 128×128 were acquired,
FOV = 1.8 cm×1.8 cm, slice
thickness = 0.5 mm, interslice
distance = 1 mm, overall acquisition time of 2 min).At the host console measurements and data processing were performed with the
ParaVision software (version 3.02, Bruker BioSpin GmbH, Ettlingen, Germany).
Further image calculation and fitting procedures were done using
MATLAB® (The Mathworks Inc., Natick, MA, USA).During UHF-MRI measurements mice were anesthesized by 2.0% Isoflurane in
medical air (21%). The respiratory rate was monitored using an
air-balloon positioned ventrally underneath the mouse body. The body temperature
was constantly measured on the body surface and actively maintained at
37°C.
Statistical and image analysis
The extraction of brain tissue from the scalp and skull was done by manual
segmentation for each subject and time point. Packages from the FMRIB Software
Library FSL (version 4.1) [23] were used for motion correction, registration (FLIRT)
[24]
and statistical image analysis. Intra-subject linear alignment and registration
to a common standard template [25] was achieved by a
step-wise affine procedure with six degrees of freedom. For voxel-wise
statistical analyses, the global CBF maps were normalized by the overall average
CBF value of the contralateral hemisphere.CBF values early (at 2 h) and at 24 h after the experimental procedure were
analysed for statistically significant voxelwise changes (24 h vs. 2 h) within
the framework of the General Linear Model and corrected for multiple comparisons
by nonparametric permutation testing using randomise, part of the FSL software
library [23].
Randomise implements the method of permutation testing based on randomisation to
correct for the multiple comparisons involved in testing across all image voxels
to adequately protect against false-positive detections as described in detail
by Nichols and Holmes [26]. For quantitative group comparisons, selected
regions-of-interest (ROIs) were delineated in atlas space: 1) the cerebral
cortex in the center of the MCA territory 2) the subcortex including the
ipsilateral caudoputamen and pyramidal tract. Statistical analysis of ROIs was
done by a 2×2 repeated measures ANOVA with factors of
GROUP (MCAO anti-GPIb;
MCAO controls) between-subjects,
and TIME (2 h; 24 h) within-subjects. Additional groups to
control for the experimental procedure (Sham controls,
N = 3) and to control for recanalization and reperfusion
(MCAO anti-GPIb,
N = 6) were analyzed separately. The risk of cerebral
infarction was determined on within-group probability maps by averaging binary
segmentations results of healthy vs. infarcted brain tissue within-subject. For
each animal binary segmentation of cerebral infarction was performed in an
automated fashion by applying a threshold of 34 ms T2 relaxation time on the T2
relaxometric maps at 24 h. Among different segmentation results for stepwise
increasing T2 relaxation times, this cut off showed best agreement with visual
delineation of infarction on T2-w imaging and with histological
2,3,5-triphenyltetrazolium chloride stain in selected subjects. Manual input was
given only for the removal of intraventricular CSF. In addition, whole-brain
volumetric analysis of infarcted tissue was retrieved by manual segmentation on
T2-w RARE images.
Results
Cerebral perfusion in naive controls and anti-GPIb treated
mice after transient and permanent MCAO
In naive control mice hypoperfusion extended over cortical and subcortical
ROI's in the center of the MCA territory at 2 h and was followed by a
significant further decrease in CBF at 24 h after
MCAO (cortical CBF (ml/100 mg/min):
40.9±4.4 (2 h) vs. 26.0±3.2 (24 h),
p = 0.022; subcortical CBF: 33.6±4.3 (2 h) vs.
24.8±3.2 (24 h), p = 0.009). In contrast,
anti-GPIb treated mice showed significant reperfusion of
the cortex (44.2±6.9 (2 h) vs. 60.5±8.4 (24 h),
p = 0.037). In the subcortex, initial CBF of the
anti-GPIb group was higher than in controls
(33.6±4.3 (controls at 2 h) vs. 45.3±5.9
(anti-GPIb at 2 h), p = 0.047).
Subcortical CBF remained stable at 24 h in anti-GPIb treated
mice (46.9±7.5) but further declined in controls (24.8±3.2). Table 1 gives an overview of
mean CBF values within cortical and subcortical ROI's in the center of the
MCA territory.
Table 1
All outcome measures per group, time point and location.
Controls
Anti-GPIb
CBF (ml/100 mg/min) 2 h vs. 24 h
Cortex
40.9±4.4 vs. 26.0±3.2
44.2±6.9 vs. 60.5±8.4
Subcortex
33.6±4.3 vs. 24.8±3.2
45.3±5.9 vs. 46.9±7.5
ADC
(mm2/s*10−4) 2 h vs. 24
h
Cortex
6.48±0.27 vs. 5.75±0.23
7.88±0.28 vs. 7.53±0.26
Subcortex
6.08±0.60 vs. 5.29±0.33
7.86±0.33 vs. 7.12±0.26
qT2 (ms) 2 h vs. 24 h
Cortex
37.24±1.96 vs. 60.05±3.15
28.6±0.4 vs.29.0 ±0.97
Subcortex
33.41±1.05 vs. 49.89±3.15
30.6±0.3 vs. 37.4±2.2
Probability of Infarction (%) 2 h vs.
24 h
Cortex
60.9±9.3 vs. 95.1±2.8
17.4±2.1 vs. 34.5±8.1
Subcortex
79.1±9.9 vs. 100±0
21.5±7.9 vs. 64.8±14.5
Values are expressed as group means and corresponding standard
errors. As the main finding sustained reperfusion was observed in
anti-GPIb treated mice, whereas controls
exhibited significant progression of hypoperfusion from 2 h to 24 h.
In the cortex of the MCA territory, reperfusion significantly
increased from 2 h to 24 h in anti-GPIb treated
mice presumably related to a larger capacity of collateral blood
flow as compared to the subcortex. In the subcortex of
anti-GPIb treated mice, improved reperfusion as
compared to controls was reflected by a significantly higher
baseline CBF at 2 h. Sustained reperfusion both in the cortical and
subcortical territory of the MCA was associated with a protection
from cerebral infarction as evident by a low probability of
infarction.
Values are expressed as group means and corresponding standard
errors. As the main finding sustained reperfusion was observed in
anti-GPIb treated mice, whereas controls
exhibited significant progression of hypoperfusion from 2 h to 24 h.
In the cortex of the MCA territory, reperfusion significantly
increased from 2 h to 24 h in anti-GPIb treated
mice presumably related to a larger capacity of collateral blood
flow as compared to the subcortex. In the subcortex of
anti-GPIb treated mice, improved reperfusion as
compared to controls was reflected by a significantly higher
baseline CBF at 2 h. Sustained reperfusion both in the cortical and
subcortical territory of the MCA was associated with a protection
from cerebral infarction as evident by a low probability of
infarction.Correspondingly, on voxel-wise analysis, clusters of significant perfusion
activation (reperfusion) and deactivation (deterioration of hypoperfusion) were
found. In anti-GPIb treated mice reperfusion was located in the
cortex, mainly in the distribution of the middle and posterior cerebral artery.
In control mice, however, hypoperfusion deteriorated in the center of the
cortical territory of the middle cerebral artery and in a smaller temporobasal
cluster in the distribution of the posterior cerebral artery. Figure 1 shows the location of
significant clusters of perfusion activation/deactivation in standard space
(blue overlay for the contrast 2 h>24 h; yellow overlay for the contrast 24
h>2 h).
Figure 1
CBF and statistical maps of voxel-wise group comparisons.
Sustained reperfusion is demonstrated by significantly elevated cortical
perfusion in anti-GPIb treated mice as compared to
persisting severe hypoperfusion in control mice. Color maps of mean CBF
are given for each group and time point (left, CBF). The results of
voxel-wise statistical analyses of change in CBF over time are shown on
the statistical parameter maps (right, Statistical maps). The spatial
distribution of significant reperfusion in the
anti-GPIb treated group is indicated by the yellow
overlay (yellow contrast of 24 h>2 h). The spatial distribution of
significant deterioration of hypoperfusion in control mice after
MCAO is indicated by blue
overlay (blue contrast of 2 h>24 h).
CBF and statistical maps of voxel-wise group comparisons.
Sustained reperfusion is demonstrated by significantly elevated cortical
perfusion in anti-GPIb treated mice as compared to
persisting severe hypoperfusion in control mice. Color maps of mean CBF
are given for each group and time point (left, CBF). The results of
voxel-wise statistical analyses of change in CBF over time are shown on
the statistical parameter maps (right, Statistical maps). The spatial
distribution of significant reperfusion in the
anti-GPIb treated group is indicated by the yellow
overlay (yellow contrast of 24 h>2 h). The spatial distribution of
significant deterioration of hypoperfusion in control mice after
MCAO is indicated by blue
overlay (blue contrast of 2 h>24 h).In contrast, anti-GPIb treated mice with permanent vessel
occlusion (MCAO) experienced progression of
severe hypoperfusion (2 h: 42.9±11.5 vs. 24 h: 35.4±5.2) and
developed extended complete MCA infarctions (not shown) similar to naive
controls. This indicates that anti-GPIb treatment is
ineffective after permanent vessel occlusion. Sham operated control mice
(N = 3) did not exhibit any perfusion abnormalities at 2 h
or 24 h after the experimental procedure and did not develop cerebral
infarctions (Figure 1).In line with the results at 2 h and 24 h, increased cortical CBF was also
observed 1 h after tCMAO (1 h: 28.2±3.5 ml/100 g/min vs. 24 h:
110.09±10.0; n = 4/group;
p = 0.002). This effect was still robust when evaluating
CBF ratios between ipsilateral and contralateral mirror ROIs: (1 h:
0.19±0.01 vs. 24 h: 0.56±0.06; p = 0.005). In
addition, quantitative cortical and subcortical T2 values (ms) representing
infarct probability in these areas were similar in comparison with the original
group of anti-GP1b treated mice measured at 2 h and 24 h
(cortical ROI 1 h: 30.6±0.7 vs. cortical ROI 24 h: 32.2±2.1;
subcortical ROI 1 h: 30.8±0.3 vs. subcortical ROI 24 h:
45.7±2.4).
Probability of cerebral infarction and quantitative ADC values in naive and
anti-GPIb treated mice
Cerebral infarction was determined on T2 relaxometric images by binary
segmentation at a threshold of 34 ms. This cut-off was previously demonstrated
to give accurate estimates of infarct extension at 17.6 Tesla field strength
[15]. Figure 2 shows that the
cut-off value of T2 = 34 ms yields best results of infarct
extension when comparing the results of a stepwise segmentation procedure with
increasing quantitative T2 thresholds as compared to high resolution T2-w RARE
imaging.
Figure 2
Results of automated stepwise binary segmentation of cerebral
infarction.
Different segmentation results are displayed for increasing quantitative
T2 values. Accurate estimates of the extent of cerebral infarction as
compared to high-resolution T2-w imaging (upper left) and histological
stains with 2,3,5-triphenyltetrazolium chloride were achieved for a
segmentation threshold of T2 = 34 ms. Delineation
of infarction was performed on T2 relaxometric images at 24 h after the
experimental procedure.
Results of automated stepwise binary segmentation of cerebral
infarction.
Different segmentation results are displayed for increasing quantitative
T2 values. Accurate estimates of the extent of cerebral infarction as
compared to high-resolution T2-w imaging (upper left) and histological
stains with 2,3,5-triphenyltetrazolium chloride were achieved for a
segmentation threshold of T2 = 34 ms. Delineation
of infarction was performed on T2 relaxometric images at 24 h after the
experimental procedure.Probability maps of cerebral infarction were rendered group-wise using the
individual segmentation results of each animal. They are given along with maps
of the mean ADC for each group and time point in Figure 3. Of note, for the given segmentation
threshold, in control mice after MCAOcerebral infarction was already manifest at 2 h in the basal ganglia and covered
the complete cortical and deep MCA territory at 24 h. In
anti-GPIb treated miceinfarction did not occur with
relevant probability at 2 h after MCAO
(17.4±2.1%) and at 24 h occurred with a significantly lower
probability in the cortex and basal ganglia than in corresponding ROI's in
controls (cortex: 34.5±8.1% vs. 95.1±2.8%,
p = 0.0001; subcortex: 64.8±14.5% vs.
100±0%, p = 0.01). Quantitative T2 values
showed similar group differences. Cortical and subcortical quantitative ADC
values exhibited a significantly stronger decrease in controls than in
anti-GPIb treated mice (cortex:
p = 0.001; subcortex: p = 0.003).
Table 1 displays all
values of ADC, quantitative T2 and probabilities of infarction for each group,
ROI and time point.
Figure 3
Maps of ADC (left), quantitative T2 (qT2, middle) and probability of
infarction (right).
Measures are given as group means per time point. The lower threshold of
qT2 was chosen to be the segmentation threshold for infarction (34 ms).
Strong protection from cerebral infarction was observed in
anti-GPIb treated mice reflected by a substantially
lower probability of completed infarction as evident on ADC, qT2 and
probability maps (upper row, anti-GPIb). This finding
was most marked in the cortex of the MCA territory. In control mice
after MCAO, cerebral infarction
involved the cortex in the center of the MCA territory and the complete
deep MCA territory with high probability (lower row, controls
MCAO).
Maps of ADC (left), quantitative T2 (qT2, middle) and probability of
infarction (right).
Measures are given as group means per time point. The lower threshold of
qT2 was chosen to be the segmentation threshold for infarction (34 ms).
Strong protection from cerebral infarction was observed in
anti-GPIb treated mice reflected by a substantially
lower probability of completed infarction as evident on ADC, qT2 and
probability maps (upper row, anti-GPIb). This finding
was most marked in the cortex of the MCA territory. In control mice
after MCAO, cerebral infarction
involved the cortex in the center of the MCA territory and the complete
deep MCA territory with high probability (lower row, controls
MCAO).Whole brain volumetric measurement of cerebral infarction by manual delineation
was performed additionally and showed similar group differences between control
mice and anti-GPIb mice after
MCAO as observed by automated
segmentation in the center of the MCA territory (Figure 4).
Figure 4
Whole-brain volumetric analysis of cerebral infarction.
The whole-brain segmentation of cerebral infarction was accomplished by
visual delination on T2-w RARE images. The infarct volume is given as
percentage of the whole-brain volume. Control mice after
MCAO (left) showed extended
cerebral infarctions in the MCA territory at 24 h, preceded by smaller
subcortical infarctions at 2 h. In contrast, anti-GPIb
treated mice exhibited significantly smaller volumes of completed
infarctions (anti-GPIb vs. controls at 24 h,
*p = 0.0002). In addition, early after
MCAO at 2 h, cerebral
infarction was not detected on visual analysis corresponding to a
neglibly small probability of infarction as detected by automated
segmentation (see Figs.
3 and 5).
Whole-brain volumetric analysis of cerebral infarction.
The whole-brain segmentation of cerebral infarction was accomplished by
visual delination on T2-w RARE images. The infarct volume is given as
percentage of the whole-brain volume. Control mice after
MCAO (left) showed extended
cerebral infarctions in the MCA territory at 24 h, preceded by smaller
subcortical infarctions at 2 h. In contrast, anti-GPIb
treated mice exhibited significantly smaller volumes of completed
infarctions (anti-GPIb vs. controls at 24 h,
*p = 0.0002). In addition, early after
MCAO at 2 h, cerebral
infarction was not detected on visual analysis corresponding to a
neglibly small probability of infarction as detected by automated
segmentation (see Figs.
3 and 5).
Figure 5
Plots of all outcome measures within cortical (upper half) and
subcortical (lower half) ROI's per group and time point.
Control mice after MCAO (solid black
lines) and anti-GPIb treated mice (dashed red lines)
showed significant group differences in the postischemic course of CBF
(first column): sustained reperfusion in anti-GPIb
treated mice vs. progression of hypoperfusion in controls, which was
most marked in the cortex (Interaction GROUPxTIME;
p = 0.00001). This effect of CBF was paralleled by
a decrease in cortical and subcortical ADC in controls, but stable
cortical ADC in anti-GPIb treated mice and less severe
subcortical ADC decrease in anti-GPIb treated mice as
compared to controls (second column). The third column (qT2) indicated
severe increase in the cortical and subcortical T2 relaxation constant
over time reflecting the demarcation of irreversible tissue damage for
controls. In contrast, anti-GPIb treated mice exhibit
stable T2 values in the cortex protected from infarction and in the
subcortex exhibit only moderate increase in mean T2 as compared to
control mice consistent with a lower group probability of infarction in
this region. Probability of infarction (fourth column) by automated
segmentation of individual animals is consistently lower for
anti-GPIb treated mice, a finding most marked in
the cortex.
Intracerebral hemorrhage was not observed in any of the anti-GPIb treated mice
which is in accordance with our previous study [7].
Comprehensive group analyses of CBF response from cortical and subcortical
regions-of-interest
Outcome measures of cerebral perfusion (CBF) and completed cerebral infarction
(qT2) were calculated from cortical and subcortical ROIs as indicated in atlas
space and are plotted in Figure
5. The cortical ROI was associated with the ipsilateral cortical MCA
territory (yellow overlay in ipsilateral cortex), the subcortical location
comprised the ipsilateral caudoputamen and deep pyramidal tract (red overlay in
ipsilateral subcortex).
Plots of all outcome measures within cortical (upper half) and
subcortical (lower half) ROI's per group and time point.
Control mice after MCAO (solid black
lines) and anti-GPIb treated mice (dashed red lines)
showed significant group differences in the postischemic course of CBF
(first column): sustained reperfusion in anti-GPIb
treated mice vs. progression of hypoperfusion in controls, which was
most marked in the cortex (Interaction GROUPxTIME;
p = 0.00001). This effect of CBF was paralleled by
a decrease in cortical and subcortical ADC in controls, but stable
cortical ADC in anti-GPIb treated mice and less severe
subcortical ADC decrease in anti-GPIb treated mice as
compared to controls (second column). The third column (qT2) indicated
severe increase in the cortical and subcortical T2 relaxation constant
over time reflecting the demarcation of irreversible tissue damage for
controls. In contrast, anti-GPIb treated mice exhibit
stable T2 values in the cortex protected from infarction and in the
subcortex exhibit only moderate increase in mean T2 as compared to
control mice consistent with a lower group probability of infarction in
this region. Probability of infarction (fourth column) by automated
segmentation of individual animals is consistently lower for
anti-GPIb treated mice, a finding most marked in
the cortex.Group comparison of CBF from the cortical ROI, similar to voxel-wise image
analysis, demonstrated that the time course of CBF between both groups went in
opposite directions showing deterioration in controls (2 h: 40.9±4.4; 24
h: 26.0±3.2) and strong recovery of CBF indicating sustained reperfusion
in anti-GPIb treated mice (2 h: 44.2±6.9; 24 h:
60.5±8.5). This is reflected by the significant interaction between the
factors GROUP and TIME in the repeated
measures ANOVA (p = 0.0012,
F(1,18) = 14.63).The significant main effect of improved cortical reperfusion in
anti-GP1b treated mice in ipsilateral ROIs was still robust
when CBF ratios between ipsilateral and contralateral mirror ROIs were evaluated
(2 h: 0.31±0.070 vs. 24 h: 41±0.07;
p = 0.01).Group comparison of CBF from the subcortical ROI showed deterioration of severe
hypoperfusion in naive controls (2 h: 33.6±4.4 and 24 h:
24.8±3.2). In contrast, sustained reperfusion was observed in
anti-GPIb treated mice (2 h: 45.3±5.9 and 24 h:
46.9±7.5). The postischemic baseline value of subcortical CBF at 2 h was
significantly lower in controls than in the anti-GPIb treated
group (2 h: 33.6±4.4 vs. 45.3±5.9;
p = 0.04).Quantitative cortical T2 values were significantly different between groups
(GROUP: F(1,18) = 14.63, p<0.00001), both
time points (TIME: F(1,,18) = 35.83,
p<0.00001) and also with a strong interaction between GROUP and TIME
(GROUPxTIME: F(1,,18) = 35.83, p<0.00001).
All T2 measures are given in Table 1.The additional group of N = 4 anti-GP1b
treated mice investigated very early after tMCAO 1 h after thread removal also
exhibited strong reperfusion, which was most marked in the cerebral cortex:
28.2±3.5 ml/100 g/min (cortex at 1 h) vs. 110.1±10.0 (cortex at 24
h); p = 0.002. This effect was robust against evaluating
CBF ratios between ipsilateral and contralateral mirror ROIs: 0.19±0.01
(cortex at 1 h) vs. 0.56±0.06 (cortex at 24 h);
p = 0.005. In this additional series, the observed
quantitative T2 values (ms), and hence the probability of infarction, within the
cortical (1 h: 30.6±0.7 vs. 24 h: 32.2±2.1) and subcortical ROI (1
h: 30.8±0.3 vs. 24 h: 45.7±2.4) were similar in comparison with
the original group of anti-GP1b treated mice undergoing
measurements at 2 h and 24 h.
Discussion
This UHF-MRI study confirms and extends our previous observation that blockade of
platelet tethering in experimental cerebral ischemia prevents infarct growth.
Importantly, for the first time we show in-vivo that interfering with platelet
function can prevent naturally occurring blood flow reductions in the brain during
reperfusion. Thus, platelets are important mediators of infarct progression during
ischemia and reperfusion.GPIb-V-IX is a structurally unique receptor complex exclusively expressed in
platelets and megakaryocytes which mediates the initial tethering of platelets at
sites of vascular injury [8]. Blockade of GPIb ameliorates infarct growth in cerebral
ischemia as shown previously [7], and confirmed here, but the underlying mechanisms are
largely unknown. Tethering of platelets to the endothelial layer of the vessel wall
via GPIb/vWF binding is an important initiator of thrombus formation under high
shear conditions such as in the arterial system [3], [6], [8], [27]. On the other hand, blockade
of GPIb can prevent immune cell recruitment in the context of inflammation as shown
recently in a model of experimental peritonitis [9]. Since inflammation is more and
more recognized as a critical component in the pathophysiology of stroke [28], [29], [30], it was
conceivable that the beneficial effects of GPIb blockade on infarction are not
related to improving blood flow, but rather to ameliorating secondary
inflammation.To address this important issue we employed multimodal UHF-MRI at 17.6T in mice with
stroke allowing the measurement of cerebral blood flow in-vivo over time, through
the intact skull and with extended anatomical sampling both of deeply located brain
regions and the cortex. In addition, impending infarction was assessed by the
measurement of hypoxic diffusion restriction of free water (ADC) and quantitative T2
was evaluated as a marker for vasogenic edema paralleling completed tissue
infarction. All measures were acquired with high spatial resolution and extended
coverage to achieve segmentation of the mouse cortex from subcortical structures.
These brain regions show differences in their susceptibility to ischemia since the
neocortex has a larger capacity for collateral blood supply. Data postprocessing and
analysis included registration of all outcome measures into one anatomical standard
space to enable voxel-wise statistical comparisons on group level and the
calculation of probability maps of infarction for each group.By means of calculating probability maps of infarction for each group, we could show
that anti-GPIb treatment protects the cerebral cortex downstream of
the recanalized MCA from infarction. There was a significantly lower probability of
completed infarction in this region for anti-GPIb treated mice as
compared to controls at 24 h after MCAO
(35% vs. 95% in controls, p = 0.0001). CBF
measurements revealed that this was due to sustained reperfusion after
anti-GPIb treatment. Treated mice showed a higher CBF already
very early during reperfusion (at 1 h and 2 h after
MCAO) as compared to controls (subcortex:
45.3±5.9 vs. 33.6±4.3; cortex: 44.2±6.9 vs. 40.9±4.4)
and this difference further increased with time (subcortex at 24 h: 46.9±7.5
vs. 24.8±3.2; cortex at 24 h: 60.5±8.4 vs 26.0±3.2). Sustained
reperfusion was also observed in the basal ganglia, which, although to a lesser
degree than the cortex, were also protected from infarction in comparison with
controls. The fact that infarct protection was lost after permanent MCAO clearly
indicates that recanalization of large proximal vessels is compulsory for the
efficacy of anti-GPIb Fab fragments. The exact mode of anti-GPIb Fab action in the
context of brain ischemia/reperfusion injury still has to be established but reduced
thrombus formation or destabilisation of previously formed thrombi leading to
improved clot “washout” from the cerebral microvasculature might be
involved [15]. Since
GPIb-V-IX is a receptor complex exclusively expressed in platelets and
megakaryocytes, the stroke-mitigating effect by anti-GPIb Fab can only be explained
by an anti-platelet effect, and not by direct neuroprotection that could secondarily
improve blood flow.As an additional exploratory finding, we observed a T2 increase already 2 h after
tMCAO in control mice. This probably indicates very early vasogenic edema detectable
only at ultra-high magnetic field strengths and is in accordance with measurements
at 9.4 Tesla [31],
[32].Taken together, our study shows that preventing platelet activation can prevent
deterioration of blood flow during the reperfusion phase after transient cerebral
ischemia. Using multimodal in-vivo MRI at ultra-high magnetic field strength, wefor
the first time could verify increased microvascular patency early during reperfusion
in the wake of anti-GP1b treatment which is supported by previous histological data
[33]. These
results further support the concept that platelets play an important role in
mediating infarct progression during early ischemia and successive reperfusion.
Thus, GPIb, and its downstream signalling pathways via phospholipase D1 [34] may be
promising new targets to combat acute ischemic stroke in the future.
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Simon F De Meyer; Tobias Schwarz; Hans Deckmyn; Cécile V Denis; Bernhard Nieswandt; Guido Stoll; Karen Vanhoorelbeke; Christoph Kleinschnitz Journal: Arterioscler Thromb Vasc Biol Date: 2010-07-08 Impact factor: 8.311
Authors: Björn Petri; Andre Broermann; Hang Li; Alexander G Khandoga; Alexander Zarbock; Fritz Krombach; Tobias Goerge; Stefan W Schneider; Claire Jones; Bernhard Nieswandt; Martin K Wild; Dietmar Vestweber Journal: Blood Date: 2010-08-17 Impact factor: 22.113
Authors: Allan MacKenzie-Graham; Erh-Fang Lee; Ivo D Dinov; Mihail Bota; David W Shattuck; Seth Ruffins; Heng Yuan; Fotios Konstantinidis; Alain Pitiot; Yi Ding; Guogang Hu; Russell E Jacobs; Arthur W Toga Journal: J Anat Date: 2004-02 Impact factor: 2.610
Authors: Christoph Kleinschnitz; Peter Kraft; Angela Dreykluft; Ina Hagedorn; Kerstin Göbel; Michael K Schuhmann; Friederike Langhauser; Xavier Helluy; Tobias Schwarz; Stefan Bittner; Christian T Mayer; Marc Brede; Csanad Varallyay; Mirko Pham; Martin Bendszus; Peter Jakob; Tim Magnus; Sven G Meuth; Yoichiro Iwakura; Alma Zernecke; Tim Sparwasser; Bernhard Nieswandt; Guido Stoll; Heinz Wiendl Journal: Blood Date: 2012-11-15 Impact factor: 22.113
Authors: Vanessa H Brait; Thiruma V Arumugam; Grant R Drummond; Christopher G Sobey Journal: J Cereb Blood Flow Metab Date: 2012-02-01 Impact factor: 6.200